ArticleBMC biotechnology2025
Protective effect of Lycopene/Lycopene cubosomal nanoparticles against cisplatin-induced cardiotoxicity: the function of NF-ҡB/HO-1 and Sirt1/AMPK/PGC1-α signaling pathways.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gastrodin mitigates cisplatin-induced cardiotoxicity in Swiss albino mice by restoring redox homeostasis and modulating the p62-Keap1-Nrf2 Axis.Molecular biology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOne antineoplastic agent with a wide variety of anticancer properties is Cisplatin (Cis). The strong antioxidant lycopene has garnered a lot of interest from researchers due to its possible health advantages. The purpose of this work was to determine probable mechanisms behind the cardioprotective benefits and explore the innovative application of Lycopene Nanoformulation to reduce Cis-induced cardiotoxicity.
methodsLycopene-Cub-NPs were characterized using particle size, zeta potential, PDI, SEM, TEM, and FTIR. Rats were allocated into seven groups: (1) Control, (2) Control polymer, (3) Lycopene Free, (4) Lycopene-Cub-NPs, (5) Cis, (6) Lycopene Free + Cis, and (7) Lycopene-Cub-NPs + Cis, with Cis (10 mg/kg, I.P.) administered once on day 27 to groups 5–7. The oxidative stress markers MDA, CAT, SOD, GSH, GPX-1, and GST in heart tissue were measured using ELISA. The content of PGC1-α, AMPK, IL-10, HO-1, Cytochrome c, Caspase 9, and BAX was also measured using ELISA. The relative gene expression of Sirt1, AMPK, PGC1-α, NF-ҡB, IL-10, HO-1, Caspase 3, and Bcl-2 was evaluated by qRT-PCR using β-actin as a housekeeping gene.
resultsCis dramatically raised the activity of the heart damage markers CK-MB and LDH. Catalase and superoxide dismutase activities were reduced, while myocardial MDA content rose as well. Similarly, Cis exhibits a notable downregulation in Sirt1, AMPK, PGC1-α, IL-10, HO-1, and Bcl-2, and an elevation in the NF-ҡB, Cytochrome c, Caspase 9, BAX, and Caspase 3 gene and protein expression. Pretreatment with Lycopene-Cub-NPs demonstrated the strongest recovery of the altered histological, immunohistochemical, and biochemical features as compared to Lycopene Free.
conclusionThis study demonstrated that Lycopene-Cub-NPs mitigate Cis-induced cardiotoxicity in vivo, likely through antioxidant, anti-inflammatory, and anti-apoptotic mechanisms, supporting their potential as a novel cardioprotective strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.